

M  
L

Internal  
Correspondence

FILE

Dr. C. Prince

RECEIVED

NOV 12 1985

M. E. HRINDA, Ph.D.

DATE: November 8, 1985

TO: To the Record

cc: M. Hrinda, Ph.D.  
James O'Brien  
Alain Schreiber, M.D.  
Charles Smith, M.D.


FROM: William Terry, M.D. WOT

SUBJECT:

Through the efforts of Bernie Loev, we were able to determine that there is a contractual arrangement with Dr. Prince which precludes him from publishing, without our approval, data from experiments supported by RMCG. Dr. Prince submitted a manuscript to me entitled "Safety of Blood Derivatives Pasteurized in the Dry State." The data in this manuscript indicate that Generation I, Generation II and Factor IX are not rendered virus-free when they have been contaminated with HTLV-III and heated in the dry state at 60° for even as much as 72 hours. I told Dr. Prince that while our foremost concern was the safety of patients receiving these products, these data taken in isolation could only be confusing to the scientific community, the treatment community, and the public and that we therefore were not prepared to give him permission to publish. I pointed out the discrepancies between both his test system and his test system results when compared with the data reported by McDougal and others. I indicated that we certainly wished to continue working with him and hoped that we could do a more comprehensive study, utilizing his sensitive test system, but applying it to the heating conditions and the products of all of the major suppliers.

While Dr. Prince was obviously disappointed and somewhat contentious, he accepted the fact he would not be able to publish these data and the conversation ended on a reasonably cordial note.

WOT:jp



CONFIDENTIAL  
SUBJECT TO PROTECTIVE ORDER  
CIVIL ACTION NO. 85-178 OR 85-699  
R 12871

EXHIBIT 06

A003575